Atrial fibrillation (AF) is an independent risk factor for intracranial hemorrhage in patients receiving recombinant-tissue-type plasminogen activator (rt-PA) thrombolytic therapy. Research showed that patients with acute ischemic stroke (AIS) could benefit from multimode computed-tomography-(CT-) guided intravenous thrombolysis over 4.5 hours. The medical data of patients with AIS in our center were retrospectively reviewed, and the data of the multimode CT-guided thrombolytic therapy or nonthrombolytic therapy within different time windows (3-9 hours) were evaluated. 134 AIS cases were selected successfully and divided into three groups: patients with AF treated by rt-PA (AF rt-PA), patients with AF not treated by rt-PA (AF non-rt-PA), and patients without AF treated by rt-PA (non-AF rt-PA). After correcting for the baseline NIH Stroke Scale (NIHSS), sex, age, and hypertension data, the comparison results showed that the NIHSS improved significantly at hospital discharge for rt-PA-treated patients (n = 47) compared to non-rt-PA-treated patients with AIS (n = 31) with AF (P = 0.0156). The NIHSS evaluation at 90 days of follow-up also improved in rt-PA-treated patients (P = 0.0157). The NIHSS at hospital discharge was higher in AF rt-PA-treated patients compared to non-AF rt-PAtreated patients (P = 0.0167) after correction; the difference was not statistically significant at 90 days of follow-up (P = 0.091). Our research showed that the neural function improved after 3-9 hours of thrombolytic therapy with rt-PA in patients with AIS and AF. If there is no thrombolytic taboo, the patients could benefit from the thrombolytic therapy, although the onset time window has been extended to 9 hours.
A cute ischemic stroke (AIS) accounts for about 70 80% of all stroke cases. 1) Up to now, ultraearly thrombolysis and antiplatelet therapy have been supported by evidence-based research in treating ischemic stroke. [2] [3] [4] In addition, compelling studies have demonstrated that intravenous thrombolysis with recombinant-tissue-type plasminogen activator (rt-PA) within 3 hours of onset significantly reduced the risk of death and severe disability from stroke. 5) Atrial fibrillation (AF) has been established as a major risk factor for ischemic stroke. In a recent cohort study, 6) it was reported that patients with a history of AF account for 22.2% of patients with prior stroke and for 7.4% of subjects without prior stroke. Zhao, et al. indicated that previous AF is associated with hemorrhagic complications in patients with AIS treated by intravenous alteplase within 4.5 hours after stroke. 7) Furthermore, a recent systematic review and meta-analysis demonstrated that AF is associated with poor outcomes in thrombolyzed patients with AIS. 8) These studies was performed to identify the effect of thrombolysis in AIS patients with AF in clinical, which could be helpful in the selection of patients who could benefit from thrombolysis.
Frank, et al. 9) analyzed the thrombolytic effect of rt-PA in patients with AIS and AF in the Virtual International Stroke Trials Archive (VISTA). They indicated that, compared with non-AF thrombolytic patients, although the NIH Stroke Scale (NIHSS) baseline was high and the age was older, AF had no adverse effect on the outcome of thrombolytic treatment. In addition, the clinical outcome for patients with AF receiving thrombolytic therapy was better compared to nonthrombolytic patients. In particular, Sung, et al. 10) stratified the stroke severity in patients with stroke and AF, and they found the same result. As we reported previously, 11) for patients with stroke and AF, the ones who received rt-PA therapy had better clinical bene-THROMBOLYSIS IN PATIENTS WITH AIS WITH ATRIAL FIBRILLATION fits compared to the ones who did not receive thrombolytic therapy. The conflicting outcomes of thrombolytic therapy for patients with stroke and AF might be due to different clinical designs.
The thrombolysis time window of 4.5 hours is very narrow with limited benefits. Many clinicians are currently seeking different techniques to expand this thrombolytic time window. With the continuous development of neuroimaging technology, a series of clinical trials have demonstrated encouraging results of thrombolysis in treating AIS using multiparametric magnetic resonance imaging. Moreover, the safety and efficacy of computed-tomographyperfusion-(CTP-) guided intravenous thrombolysis for AIS beyond 4.5 hours have been proven in an exploratory study. 12) In this exploratory study, the symptomatic hemorrhagic transformation and good long-term outcome were similar between patients who received thrombolysis within and beyond 4.5 hours after the stroke onset. In the same year, the Third International Stroke Trial (IST-3) collaborative group 13) suggested that the time window for thrombolysis can be extended to 6 hours; within a 6 hours' time window, 70% of patients with AIS had an ischemic penumbra area. This could increase the chance of patients receiving thrombolytic therapy.
However, the safety and benefits of thrombolytic therapy with a prolonged time window have been reported in few studies in patients with AIS and AF. In our previous work, we demonstrated that patients with AIS and AF could benefit from rt-PA therapy as compared to non-AF rt-PA-treated patients. 11) Currently, in our real-world study, we retrospectively analyzed the effectiveness and safety of rt-PA with a prolonged time window in patients with AIS. Here, we report further analyses of the thrombolysis effect in patients with AIS combined with AF under a prolonged time window. This real-world research may provide some useful information for the optimization of clinical diagno-ses and more effective treatment of patients with AIS and AF.
Methods

Patients and study design:
This study was a singlecenter, retrospective, clinical study. The medical data of the patients with AIS from June 2008 to December 2017 were reviewed. Figure 1 shows a flowchart of our study. The data of the multimode CT-guided rt-PA thrombolytic therapy with different time windows was evaluated. This study was approved by the Ethical Committee of the Third People's Hospital of Dalian with registration number ChiCTR1800014368.
The following medical information of the patients was recorded and analyzed: demographic data, imaging data (CT and MR), electrocardiogram examination, laboratory examination, NIHSS, Barthel's Index (BI), and modified Rankin Scale (mRS) score. The follow-up results of the patients at hospital discharge and at 90 days were also recorded for analysis. The CT examination results, including CT plain scan, CTP imaging, and CT angiography (CTA), were all collected. The images were qualitatively evaluated using methods that we described previously. 11) Symptomatic intracranial hemorrhage (sICH) was defined as reported previously by Strbian, et al. 14) Inclusion and exclusion criteria: The inclusion criteria were as follows: (1) the patient is aged between 18 and 80; (2) the time window for new stroke symptoms or signs from onset to treatment (OTT) time is within 3-9 hours; (3) ischemic stroke is clinically diagnosed, assessed with neural function defects (e.g., language, motor function, and cognitive impairment; gaze disorder; visual field defect; and/or visual neglect) (ischemic stroke is defined as a sudden onset of acute focal neurological deficits, presumably due to cerebral ischemia, with cerebral hemor-rhage ruled out by CT); (4) the first onset or previous stroke did not cause significant sequelae (mRS < 2); (5) the patient have the symptoms of thrombolysis and the main evaluation data could be collected; (6) patients with AF have a prior documented history (electrocardiogramdetermined AF); and (7) the detailed imaging criteria include (i) not conforming to the CT scan exclusion criteria, (ii) original CTA showing an abnormal low-density area of the involved cerebral hemisphere with a diameter of > 2 cm and a low-density area < 1/3 of the middle cerebral artery (MCA) area, (iii) an abnormal area of CTP (> 20% abnormal low-density area of the original CTA area), (iv) thrombolysis in cerebral infarction grade 0 or 1 (large vascular occlusion or serious) demonstrated by CTA.
The exclusion criteria were as follows: (1) patients had a previous stroke and obvious sequelae (mRS > 2); (2) coma or clinical assessments (e.g., NIHSS > 25) and/ or other imaging findings confirmed severe stroke; (3) heparin was applied within 48 hours before the onset and activated partial thromboplastin time (aPTT) exceeded the upper limit of the normal value; (4) creatinine > 133 μmol/L; (5) thrombocytopenia < 100,000/mm 3 ; (6) high blood pressure (systolic blood pressure [SBP] > 185 mmHg or diastolic blood pressure [DBP] > 110 mmHg) not controlled after active antihypertensive treatment; (7) blood glucose < 50 mg/dL (2.7 mmol/L) or > 400 mg/dL (22.2 mmol/L); (8) significant hemorrhagic diseases in the past 6 months; (9) a history of intracranial hemorrhage or a suspicion of it; (10) pregnancy or lactation; (11) severe central nervous system damage, hemorrhagic retinopathy, bacterial endocarditis, acute pancreatitis, or any other disease not appropriate to be included in this study, as judged by the researches; and (12) detailed imaging exclusion criteria including (i) cerebral hemorrhage and subarachnoid intracranial tumor, (ii) dense hemorrhage of the brain demonstrated by CT, (iii) marked signs of midline shift due to massive cerebral infarction, (iv) low-density shadow and faint blurring in the area beyond the 1/3 distribution of the MCA or suspected infarct lesion. CT scan: Multislice spiral CT (40 rows or more) was used for whole brain scan. The plane scan is based on the connection between the auditory and the orbital lines and avoids direct lens exposure. The scan range was the base of the skull to the head; the thick surface of the skull was 3-5 mm and was 8-10 mm to the cerebral hemisphere. CTP images were processed using unified image postprocessing software. Postprocessing of maximum intensity projection (MIP) and/or volume rendering was used for CTA image. At least one CTA parameter was contained in MIP image, which including the ring of Willis. The thickness of the reconstructed CTA image from the raw data was consistent with CTP, and the scanning parameters of CT and multimodal CT were consistent in the patients. Specific therapy for AIS: As for AIS indicating to intervene in the process of injury, all procedures conformed to the guiding principles of the year. Information including the time of thrombolytic therapy, the dose of thrombolytic agents, the dose of rt-PA reagents, and the other commonly used drugs was collected. The other commonly used drugs included (1) antiplatelet agents (aspirin and clopidogrel), (2) anticoagulant drugs (heparin, low-molecular-weight heparin, heparinoids, oral anticoagulants, and thrombin inhibitors), (3) plasma volume extenders (hydroxyethyl starch and low-molecular-weight dextran), (4) neuroprotective agents (e.g., edaravone), and (5) cerebral blood perfusion improving agents (butylphthalide, human urinary kallidinogenase). Outcomes evaluation: The main measured outcome was the change of the NIHSS score at discharge and at 90-day follow-up. Other outcome measures included the incidence of postthrombolytic bleeding events, nerve function improvement after thrombolysis, mRS score, and adverse outcomes at discharge or 90 days after treatment. Statistical analysis: The NIHSS data was expressed as the mean ± standard deviation, and the normal distribution and variance homogeneity were compared using Student's test or analysis of variance. Bonferroni test was used for further comparisons. Otherwise, the Kruskal-Wallis method was used for statistical tests, the grouped Wilcoxon rank sum test was used for further analyses, and the Bonferroni method was used to correct P-values for paired comparisons. The paired t-test or Wilcoxon's signed-rank test was used to analyze the measurement data between two groups. Descriptive data, such as the proportion of patients, were expressed by the number and proportion of their respective cases, and the differences were compared with the chi-squared or Fisher's exact test. If the difference between the groups was statistically significant, the Bonferroni test was used for further paired comparisons. P < 0.05 was considered statistically significant.
Results
Demographic data of the included patients:
A total of 321 medical cases with OTT time within 3-9 hours were screened. 134 AIS cases were selected successfully for our subgroup analysis, and they were divided into three groups according to whether or not using rt-PA or combining AF: patients with AF treated by rt-PA (AF rt-PA), patients with AF not treated by rt-PA (AF non-rt-PA), and patients without AF treated by rt-PA (non-AF rt-PA). The demographic characteristics of these patients are listed in Table I . Preliminary comparison shows that the age of the patients with AF was significantly higher compared to non-AF patients (P = 0.025). Non-AF patients had a higher male/female ratio and a lower hypertension ratio (P = 0.036 and 0.032, respectively). No significant difference was observed in terms of smoking, drinking, diabetes, and other common severe diseases between the three groups. Laboratory data: The recorded average OTT time was shorter and the degree of nerve function defect (evaluated by the NIHSS score) was more serious in patients with AF compared to non-AF patients (Table II) . The lowdensity lipoprotein cholesterol (LDL-c) and platelet (PLT) count were higher, whereas the triglyceride (TG) and international normalized ratio (INR) were lower in patients with AF treated by rt-PA (AF rt-PA group) compared to those without AF treated by rt-PA (non-AF rt-PA) (all P < 0.05). NIHSS change after thrombolysis: The change of the NIHSS score from baseline to hospital discharge was THROMBOLYSIS IN PATIENTS WITH AIS WITH ATRIAL FIBRILLATION compared in 134 patients with AIS (Table III) . Although the baseline NIHSS score was obviously higher in the AF rt-PA group compared to the non-AF rt-PA group (11.5 ± 4.8 versus 9.3 ± 4.9, P = 0.020), the NIHSS score at hospital discharge exhibited no difference between the two groups. For patients with AF, the baseline NIHSS score exhibited no difference, whereas the improved NIHSS score was better in rt-PA-treated patients than in non-rt-PA-treated patients (−4.9 ± 3.2 versus −2.9 ± 2.3, P = 0.016).
Comparison of the efficacy and safety of rt-PA with non-rt-PA reagents in patients with AIS and AF:
After correcting for the baseline NIHSS score, sex, age, and hypertension at the same level in patients with AIS, we com-YANG, ET AL pared the NIHSS changes after thrombolysis in AF rt-PAtreated patients and non-AF rt-PA-treated patients. The results (Table IV) showed that the NIHSS score improved significantly at hospital discharge for rt-PA-treated patients (n = 47) compared to non-rt-PA-treated patients (n = 31) (P = 0.016). The NIHSS score at 90 days of follow-up also showed an improvement in rt-PA-treated patients compared to non-rt-PA-treated patients (P = 0.016), whereas the NIHSS score almost did not change in non-rt-PA-treated patients (10.1 ± 6.8 at hospital discharge, 10.1 ± 7.4 at 90 days of follow-up). Furthermore, the living ability, evaluated by BI and mRS (Figure 2) , improved significantly in rt-PA-treated patients compared to non-rt-PA-treated patients (P = 0.009, 0.0081 at hospital discharge; P = 0.001, 0.009 at 90 days of follow-up, respectively). Recanalization was significantly higher in rt-PAtreated patients compared to non-rt-PA-treated patients (23/46 versus 1/31, P = 0.004). On the other hand, the adverse events exhibited no difference between rt-PA-treated and non-rt-PA-treated patients in terms of death during hospitalization, death after hospital discharge, intracranial hemorrhage, and bleeding. These data demonstrated the safety of rt-PA.
Efficacy of rt-PA in treating patients with AIS:
After correcting for the baseline NIHSS score, sex, age, and hypertension in AF rt-PA-treated patients (n = 44) and non-AF rt-PA-treated patients (n = 56), the efficacy and safety of rt-PA in these patients were compared. As Table IV shows, the NIHSS score at hospital discharge was higher in AF rt-PA-treated patients compared to non-AF rt-PAtreated patients (P = 0.0167), but the difference was not statistically significant at 90 days of follow-up (P = 0.091). In addition, the BI levels at hospital discharge and at 90 days of follow-up exhibited no difference between the two groups, whereas the number of AF rt-PA-treated patients whose mRS was between 0 and 1 at hospital discharge and at 90 days of follow-up was higher (Figure 3 ), which means that although patients with AF have a higher NIHSS score at hospital discharge, they still benefit from rt-PA treatment after prolonged time windows. Furthermore, sICH in AF rt-PA-treated patients was lower compared with non-AF rt-PA-treated patients (1/46 versus 2/ 54, P = 0.229). The recanalization rate was higher in AF rt-PA-treated patients compared to non-AF rt-PA-treated THROMBOLYSIS IN PATIENTS WITH AIS WITH ATRIAL FIBRILLATION patients (P = 0.006).
Safety of rt-PA in treating patients with AIS:
We further assessed the safety of rt-PA, and the results showed that the rate of death after hospital discharge exhibited no difference between AF rt-PA-treated patients and non-AF rt-PA-treated patients (Table IV ). In addition, the rate of death during hospitalization and sICH were relatively lower in AF rt-PA-treated patients, whereas the differences were not significant (3/44 versus 3/53, P = 0.434; 1/46 versus 2/54, P = 0.029, respectively). Bleeding in AF rt-PA-treated patients was also significantly lower compared with non-AF rt-PA-treated patients (8/38 versus 13/43, P = 0.040). The rates of death during hospitalization and death after hospital discharge were relatively higher in AF rt-PA-treated patients, which were not related to the sICH rate but to the age and severity of AIS.
Discussion
Currently, venous rt-PA intervention within 4.5 hours has been proven to be an effective treatment for AIS and is recommended by multiple international guidelines. 15, 16) RCT researches 17, 18) have confirmed that patients with mismatch evaluated by images could benefit from thrombolytic therapy with prolonged time windows (WAKE-UP study, MR WITNESS Research). It is well known that AF is one of the predictors of severe stroke and early death. 9, [19] [20] [21] A large number of random control trials on thrombolysis in patients with AF demonstrated that the incidence of stroke combined with AF ranged from 20% to 42%. 22, 23) So far, there is no comparison between intravenous thrombolytic therapy by rt-PA and placebo in patients with AF. It has been pointed out in previous studies that stroke combined with AF predicts poor outcomes. 9, 19, 20, 24) Patients with stroke combined with AF have greater infarct sizes, greater low-perfusion volumes, and worse collateral circulation, 25) which lead to worse baseline symptoms. 19, 26) However, the benefits of intravenous rt-PA thrombolysis in patients with AIS and AF are still controversial. Kimura, et al. 27) reported that the intrave-nous thrombolytic effect of rt-PA was worse in patients with AF compared with patients without. We speculate that this might have been caused by the relatively low dose of rt-PA, 0.6 mg/kg, which is lower than the international approved dose of 0.9 mg/kg. This is because a low dose of rt-PA may lead to a low blood vessel recanalization rate, which may subsequently lead to worse clinical outcomes of intravenous thrombolysis in patients with AF.
Unlike what was reported in the above researches, it has been indicated in some other studies that patients with AIS and AF could benefit from intravenous rt-PA thrombolysis. 10, 11, 28, 29) Abdul-Rahim, et al. 30) analyzed the data of patients with AIS in VISTA. They showed that, compared with those without AF, although patients with AIS and AF have higher baseline NIHSS scores and ages, no bad outcome was found in patients with AIS combined with AF after rt-PA thrombolytic therapy. Furthermore, the treatment effect of rt-PA was better than that of nonthrombolytic therapy in patients with AF. The authors considered that intravenous rt-PA can be used in patients with AIS and AF. In particular, after stratifying the severity of stroke in patients with stroke combined with AF, Sung, et al. 10) found that the benefit of rt-PA in patients with AF with an NIHSS score of > 10 was the same compared with non-AF rt-PA-treated patients. As we previously reported in a case-control study, 11) patients with AF who received rt-PA treatment had better clinical benefits compared to non-rt-PA-treated patients.
The thrombolytic therapy of rt-PA is limited in clinical practice because of its limited intervention time window and the possible risk of intracranial hemorrhage. The 4.5-hour time window 15, 16) and simple nonenhanced CT cannot accurately define the pathophysiology of acute ischemic brain tissue. The differences in the vascular conditions, blood flow reserve, collateral circulation quality, and ischemic tolerance made patients with AIS in urgent need to receive more individualized treatment for better benefit from thrombolytic therapy.
Therefore, ischemic penumbra (IP) has become a hotspot in the research field of ischemic stroke. On the premise of the existence of IP, the recanalization of the obliterans promotes a good clinical outcome. 23, 31) However, the prolonged ischemia time aggravates the damage of the cerebral vascular barrier, the reperfusion injury increases the risk of bleeding transformation, and the prolonged time of thrombolytic therapy consequently cannot be unlimited.
EPITHET, the first randomized controlled trial evaluating the intravenous thrombolysis effect under a prolonged time window of 6 hours, used DWI-PWI to measure IP. 31) The results showed a strong correlation between the higher reperfusion rate and the good clinical outcome in the rt-PA group and indicated that patients with mismatched images could benefit from intravenous thrombolysis with prolonged time windows. Moreover, it was shown in a meta-analysis 32) that prolonged thrombolytic time windows could achieve a good clinical outcome in patients with AIS with a mismatched area under the guidance of imaging. By combining EPITHET-DEFUSE data and other data, Ogata, et al. 31) analyzed the thrombolytic effect of patients with stroke and AF. The results showed that AF did not affect the clinical outcome and mortality at 90 days after intravenous thrombolysis within 6 hours. The latest two studies, the WAKE-UP study 17) and MR WITNESS study, 33) also showed that using imaging evaluations for unidentified stroke is safe and effective in the presence of mismatches in intravenous thrombolytic therapy.
Our results showed that, in 103 patients receiving rt-PA treatment, the OTT time ranged from 250 to 473 minutes. Patients with AIS combined with AF have higher baseline ages, male gender distribution, and NIHSS score. After correcting for these factors, the NIHSS score in patients with AF was still higher when they were discharged from the hospital, which indicated that AF does affect the rehabilitation of patients with AIS. Although the NIHSS score of patients with AF was still slightly higher than that of patients with no AF at 90 days of follow-up, the difference was not statistically significant, which indicated that the midterm recovery of patients with AF, after rt-PA treatment, was not different compared to patients with no AF. Considering the small sample size of our study, further studies may be required to confirm whether the difference will increase in larger samples.
Our study also demonstrated that the efficacy of rt-PA (NIHSS decrease, neurological function improvement BI, mRS between 0 and 1) for thrombolysis was better than that of non-rt-PA reagents for patients with AIS and AF. There was no significant difference in the prognosis of bleeding and mortality. These results suggest that if there is no thrombolytic taboo, the patients should receive rt-PA thrombolytic therapy and could benefit from rt-PA within 9 hours of AIS onset. For patients with AIS accompanied by AF, the basic principle of "time is the brain" has not changed. Our results indicated that rt-PA intravenous thrombolytic therapy within 9 hours could help patients in improving the symptoms of short-term nerve defects; rt-PA is safe and feasible. Using rt-PA in AIS combined with AF does not increase the incidence of sICH, and the prognosis of thrombolysis both at hospital discharge and at 90 days of follow-up is good. Evaluation of recanalization by vascular imaging examination further confirmed the thrombolytic effect of rt-PA. However, there are limitations in our study. First, the sample size was relatively small, and it was retrospectively analyzed. Multicenter, randomized controlled studies with larger samples are needed in the future. This could provide more clinical evidence of rt-PA for thrombolytic therapy in patients with AIS for prolonged time windows.
Conclusions
Despite the prolonged time window, patients with AIS and AF could benefit from intravenous rt-PA therapy significantly compared with non-rt-PA treatment. The recanalization rate of the rt-PA treatment group was significantly higher than that of the non-rt-PA treatment group, whereas the sICH rate and mortality rate did not increase. This provides effective evidence for rt-PA treatment in patients with AIS and AF under prolonged time windows and, furthermore, provides more benefits for patients with stroke and AF.
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